Minimal residual disease-directed therapy in acute myeloid leukemia

Blood. 2015 Apr 9;125(15):2331-5. doi: 10.1182/blood-2014-11-578815. Epub 2015 Jan 28.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Core Binding Factor Alpha 2 Subunit / genetics
  • Cytarabine / therapeutic use
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Idarubicin / therapeutic use
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Neoplasm, Residual / diagnosis
  • Neoplasm, Residual / genetics
  • Neoplasm, Residual / therapy*
  • Oncogene Proteins, Fusion / genetics
  • RUNX1 Translocation Partner 1 Protein

Substances

  • AML1-ETO fusion protein, human
  • Antineoplastic Agents
  • Core Binding Factor Alpha 2 Subunit
  • Oncogene Proteins, Fusion
  • RUNX1 Translocation Partner 1 Protein
  • Cytarabine
  • Idarubicin